{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:56:06Z","timestamp":1791410166069,"version":"4.3.3"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s43440-019-00030-z","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T11:03:06Z","timestamp":1578913386000},"page":"368-378","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Oral gavage of nano-encapsulated conjugated acrylic acid-bile acid formulation in type 1 diabetes altered pharmacological profile of bile acids, and improved glycaemia and suppressed inflammation"],"prefix":"10.1007","volume":"72","author":[{"given":"Armin","family":"Mooranian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassim","family":"Zamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina M.","family":"Ionescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryu","family":"Takechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momir","family":"Mikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Golo\u010dorbin-Kon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo\u017eica","family":"Kova\u010devi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Al-Salami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,13]]},"reference":[{"issue":"7","key":"30_CR1","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S0196-9781(01)00423-5","volume":"22","author":"JM Conlon","year":"2001","unstructured":"Conlon JM. Evolution of the insulin molecule: insights into structure-activity and phylogenetic relationships. Peptides. 2001;22(7):1183\u201393 (PMID:11569401).","journal-title":"Peptides"},{"key":"30_CR2","doi-asserted-by":"publisher","first-page":"CD011880","DOI":"10.1002\/14651858.cd011880.pub2","volume":"2","author":"SM O\u2019Neill","year":"2017","unstructured":"O\u2019Neill SM, Kenny LC, Khashan AS, West HM, Smyth RM, Kearney PM. Different insulin types and regimens for pregnant women with pre-existing diabetes. Cochrane Database Syst Rev. 2017;2:CD011880. https:\/\/doi.org\/10.1002\/14651858.cd011880.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"30_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00592-013-0505-7","volume":"51","author":"MA Vahatalo","year":"2014","unstructured":"Vahatalo MA, Viikari J, Ronnemaa T. Starting bedtime glargine versus NPH insulin in poorly controlled type 2 diabetic patients with various hyperglycemia types (fasting type or postprandial type). Acta Diabetol. 2014;51(2):233\u20138. https:\/\/doi.org\/10.1007\/s00592-013-0505-7.","journal-title":"Acta Diabetol"},{"issue":"2","key":"30_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1046\/j.1464-5491.2000.00219.x","volume":"17","author":"GR Law","year":"2000","unstructured":"Law GR, Bodansky HJ, McKinney PA. When do environmental factors initiate islet cell damage in children with Type 1 diabetes mellitus? Diabet Med. 2000;17(2):167\u20138 (PMID:11569401).","journal-title":"Diabet Med"},{"key":"30_CR5","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000060536","volume":"4","author":"HE Thomas","year":"2001","unstructured":"Thomas HE, Kay TW. How beta cells die in type 1 diabetes. Curr Dir Autoimmun. 2001;4:144\u201370 (PMID:11569401).","journal-title":"Curr Dir Autoimmun."},{"issue":"Suppl 1","key":"30_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4158\/EP.12.S1.34","volume":"12","author":"S Genuth","year":"2006","unstructured":"Genuth S. Insights from the diabetes control and complications trial\/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes. Endocr Pract. 2006;12(Suppl 1):34\u201341. https:\/\/doi.org\/10.4158\/EP.12.S1.34.","journal-title":"Endocr Pract."},{"issue":"3","key":"30_CR7","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1074\/jbc.M111.305789","volume":"287","author":"T Li","year":"2012","unstructured":"Li T, Francl JM, Boehme S, Ochoa A, Zhang Y, Klaassen CD, et al. Glucose and insulin induction of bile acid synthesis: mechanisms and implication in diabetes and obesity. J Biol Chem. 2012;287(3):1861\u201373. https:\/\/doi.org\/10.1074\/jbc.M111.305789.","journal-title":"J Biol Chem"},{"issue":"3","key":"30_CR8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.metabol.2015.10.021","volume":"65","author":"JF Vettorazzi","year":"2016","unstructured":"Vettorazzi JF, Ribeiro RA, Borck PC, Branco RC, Soriano S, Merino B, et al. The bile acid TUDCA increases glucose-induced insulin secretion via the cAMP\/PKA pathway in pancreatic beta cells. Metabolism. 2016;65(3):54\u201363. https:\/\/doi.org\/10.1016\/j.metabol.2015.10.021.","journal-title":"Metabolism."},{"issue":"5","key":"30_CR9","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3109\/00365528209181080","volume":"17","author":"OO Thomsen","year":"1982","unstructured":"Thomsen OO, Larsen JA. Interaction of insulin, glucagon, and DBcAMP on bile acid-independent bile production in the rat. Scand J Gastroenterol. 1982;17(5):687\u201393 (PMID:6294819).","journal-title":"Scand J Gastroenterol"},{"issue":"2","key":"30_CR10","first-page":"501","volume":"21","author":"J Twisk","year":"1995","unstructured":"Twisk J, Hoekman MF, Lehmann EM, Meijer P, Mager WH, Princen HM. Insulin suppresses bile acid synthesis in cultured rat hepatocytes by down-regulation of cholesterol 7 alpha-hydroxylase and sterol 27-hydroxylase gene transcription. Hepatology. 1995;21(2):501\u201310 (PMID:7843724).","journal-title":"Hepatology"},{"issue":"3","key":"30_CR11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.bbadis.2010.01.002","volume":"1802","author":"B Renga","year":"2010","unstructured":"Renga B, Mencarelli A, Vavassori P, Brancaleone V, Fiorucci S. The bile acid sensor FXR regulates insulin transcription and secretion. Biochem Biophys Acta. 2010;1802(3):363\u201372. https:\/\/doi.org\/10.1016\/j.bbadis.2010.01.002.","journal-title":"Biochem Biophys Acta"},{"issue":"1","key":"30_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/BF03190984","volume":"32","author":"M Mikov","year":"2007","unstructured":"Mikov M, Boni NS, Al-Salami H, Kuhajda K, Kevresan S, Golocorbin-Kon S, et al. Bioavailability and hypoglycemic activity of the semisynthetic bile acid salt, sodium 3alpha,7alpha-dihydroxy-12-oxo-5beta-cholanate, in healthy and diabetic rats. Eur J Drug Metab Pharmacokinet. 2007;32(1):7\u201312 (PMID:17479538).","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"8","key":"30_CR13","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.3109\/10717544.2015.1110846","volume":"23","author":"S Mathavan","year":"2016","unstructured":"Mathavan S, Chen-Tan N, Arfuso F, Al-Salami H. A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of Type-1 diabetes. Drug Deliv. 2016;23(8):2869\u201380. https:\/\/doi.org\/10.3109\/10717544.2015.1110846.","journal-title":"Drug Deliv."},{"issue":"1","key":"30_CR14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1055\/s-0042-106084","volume":"125","author":"H Al-Salami","year":"2017","unstructured":"Al-Salami H, Mamo JC, Mooranian A, Negrulj R, Lam V, Elahy M, et al. Long-term supplementation of microencapsulated ursodeoxycholic acid prevents hypertension in a mouse model of insulin resistance. Exper Clin Endocrinol Diabetes. 2017;125(1):28\u201332. https:\/\/doi.org\/10.1055\/s-0042-106084.","journal-title":"Exper Clin Endocrinol Diabetes"},{"issue":"5","key":"30_CR15","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1007\/s11095-016-1863-y","volume":"33","author":"A Mooranian","year":"2016","unstructured":"Mooranian A, Negrulj R, Al-Salami H. The influence of stabilized deconjugated ursodeoxycholic acid on polymer-hydrogel system of transplantable NIT-1 cells. Pharm Res. 2016;33(5):1182\u201390. https:\/\/doi.org\/10.1007\/s11095-016-1863-y.","journal-title":"Pharm Res"},{"issue":"2","key":"30_CR16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/10837450.2017.1321664","volume":"23","author":"A Mooranian","year":"2018","unstructured":"Mooranian A, Takechi R, Jamieson E, Morahan G, Al-Salami H. The effect of molecular weights of microencapsulating polymers on viability of mouse-cloned pancreatic beta-cells: biomaterials, osmotic forces and potential applications in diabetes treatment. Pharm Dev Technol. 2018;23(2):145\u201350. https:\/\/doi.org\/10.1080\/10837450.2017.1321664.","journal-title":"Pharm Dev Technol"},{"issue":"3","key":"30_CR17","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s13346-017-0473-5","volume":"8","author":"A Mooranian","year":"2018","unstructured":"Mooranian A, Negrulj R, Takechi R, Mamo J, Al-Sallami H, Al-Salami H. The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4\u00a0weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory effects. Drug Deliv Transl Res. 2018;8(3):543\u201351. https:\/\/doi.org\/10.1007\/s13346-017-0473-5.","journal-title":"Drug Deliv Transl Res."},{"issue":"6","key":"30_CR18","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1080\/21691401.2017.1362416","volume":"46","author":"A Mooranian","year":"2018","unstructured":"Mooranian A, Negrulj R, Takechi R, Jamieson E, Morahan G, Al-Salami H. Electrokinetic potential-stabilization by bile acid-microencapsulating formulation of pancreatic beta-cells cultured in high ratio poly-l-ornithine-gel hydrogel colloidal dispersion: applications in cell-biomaterials, tissue engineering and biotechnological applications. Artif Cells Nanomed Biotechnol. 2018;46(6):1156\u201362. https:\/\/doi.org\/10.1080\/21691401.2017.1362416.","journal-title":"Artif Cells Nanomed Biotechnol."},{"key":"30_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3389\/fnagi.2017.00399","volume":"9","author":"R Takechi","year":"2017","unstructured":"Takechi R, Lam V, Brook E, Giles C, Fimognari N, Mooranian A, et al. Blood-brain barrier dysfunction precedes cognitive decline and neurodegeneration in diabetic insulin resistant mouse model: an implication for causal link. Fronti Aging Neurosci. 2017;9:399. https:\/\/doi.org\/10.3389\/fnagi.2017.00399.","journal-title":"Fronti Aging Neurosci"},{"issue":"6","key":"30_CR20","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s11095-017-2138-y","volume":"34","author":"A Mooranian","year":"2017","unstructured":"Mooranian A, Tackechi R, Jamieson E, Morahan G, Al-Salami H. Innovative microcapsules for pancreatic beta-cells harvested from mature double-transgenic mice: cell imaging, viability, induced glucose-stimulated insulin measurements and proinflammatory cytokines analysis. Pharm Res. 2017;34(6):1217\u201323. https:\/\/doi.org\/10.1007\/s11095-017-2138-y.","journal-title":"Pharm Res"},{"key":"30_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s12195-017-0510-y","author":"A Mooranian","year":"2017","unstructured":"Mooranian A, Negrulj R, Takechi R, Jamieson E, Morahan G, Al-Salami H. Influence of biotechnological processes, speed of formulation flow and cellular concurrent stream-integration on insulin production from \u03b2-cells as a result of co-encapsulation with a highly lipophilic bile acid. Cell Mol Bioeng. 2017. https:\/\/doi.org\/10.1007\/s12195-017-0510-y.","journal-title":"Cell Mol Bioeng"},{"issue":"10","key":"30_CR22","doi-asserted-by":"publisher","first-page":"833","DOI":"10.4155\/tde-2017-0042","volume":"8","author":"A Mooranian","year":"2017","unstructured":"Mooranian A, Negrulj R, Takechi R, Jamieson E, Morahan G, Al-Salami H. Alginate-combined cholic acid increased insulin secretion of microencapsulated mouse cloned pancreatic beta cells. Ther Deliv. 2017;8(10):833\u201342. https:\/\/doi.org\/10.4155\/tde-2017-0042.","journal-title":"Ther Deliv"},{"key":"30_CR23","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.7b00220","author":"A Mooranian","year":"2017","unstructured":"Mooranian A, Negrulj R, Takechi R, Jamieson E, Morahan G, Al-Salami H. New biotechnological microencapsulating methodology utilizing individualized gradient-screened jet laminar flow techniques for pancreatic beta-cell delivery: bile acids support cell energy-generating mechanisms. Mol Pharm. 2017. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00220.","journal-title":"Mol Pharm"},{"issue":"6","key":"30_CR24","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3109\/10837450.2014.915570","volume":"20","author":"A Mooranian","year":"2015","unstructured":"Mooranian A, Negrulj R, Mathavan S, Martinez J, Sciarretta J, Chen-Tan N, et al. An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations. Pharm Dev Technol. 2015;20(6):702\u20139. https:\/\/doi.org\/10.3109\/10837450.2014.915570.","journal-title":"Pharm Dev Technol"},{"issue":"5","key":"30_CR25","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s13346-015-0248-9","volume":"5","author":"A Mooranian","year":"2015","unstructured":"Mooranian A, Negrulj R, Arfuso F, Al-Salami H. The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study. Drug Deliv Transl Res. 2015;5(5):511\u201322. https:\/\/doi.org\/10.1007\/s13346-015-0248-9.","journal-title":"Drug Deliv Transl Res."},{"issue":"1","key":"30_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1208\/s12249-014-0205-9","volume":"16","author":"A Mooranian","year":"2015","unstructured":"Mooranian A, Negrulj R, Al-Sallami HS, Fang Z, Mikov M, Golocorbin-Kon S, et al. Probucol release from novel multicompartmental microcapsules for the oral targeted delivery in type 2 diabetes. AAPS PharmSciTech. 2015;16(1):45\u201352 (PMCID:PMC4309805).","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"30_CR27","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3109\/02652048.2014.958204","volume":"32","author":"A Mooranian","year":"2015","unstructured":"Mooranian A, Negrulj R, Al-Sallami HS, Fang Z, Mikov M, Golocorbin-Kon S, et al. Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment. J Microencapsul. 2015;32(2):151\u20136. https:\/\/doi.org\/10.3109\/02652048.2014.958204.","journal-title":"J Microencapsul"},{"key":"30_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s12247-014-9182-5","author":"A Mooranian","year":"2014","unstructured":"Mooranian A, Negrulj R, Mathavan S, Martinez J, Sciarretta J, Chen-Tan N, et al. Stability and release kinetics of an advanced gliclazide-cholic acid formulation: the use of artificial-cell microencapsulation in slow release targeted oral delivery of antidiabetics. J Pharm Innov. 2014. https:\/\/doi.org\/10.1007\/s12247-014-9182-5.","journal-title":"J Pharm Innov"},{"key":"30_CR29","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.2147\/DDDT.S68247","volume":"8","author":"A Mooranian","year":"2014","unstructured":"Mooranian A, Negrulj R, Chen-Tan N, Watts GF, Arfuso F, Al-Salami H. An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer. Drug Des Devel Ther. 2014;8:1673\u201383. https:\/\/doi.org\/10.2147\/DDDT.S68247.","journal-title":"Drug Des Devel Ther."},{"key":"30_CR30","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.2147\/DDDT.S67349","volume":"8","author":"A Mooranian","year":"2014","unstructured":"Mooranian A, Negrulj R, Chen-Tan N, Al-Sallami HS, Fang Z, Mukkur TK, et al. Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol. Drug Des Devel Ther. 2014;8:1221\u201330. https:\/\/doi.org\/10.2147\/DDDT.S67349.","journal-title":"Drug Des Devel Ther."},{"key":"30_CR31","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.2147\/DDDT.S65396","volume":"8","author":"A Mooranian","year":"2014","unstructured":"Mooranian A, Negrulj R, Chen-Tan N, Al-Sallami HS, Fang Z, Mukkur T, et al. Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study. Drug Des Dev Ther. 2014;8:1003\u201312. https:\/\/doi.org\/10.2147\/DDDT.S65396.","journal-title":"Drug Des Dev Ther"},{"key":"30_CR32","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2147\/JIR.S65979","volume":"7","author":"M Fakhoury","year":"2014","unstructured":"Fakhoury M, Negrulj R, Mooranian A, Al-Salami H. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res. 2014;7:113\u201320. https:\/\/doi.org\/10.2147\/JIR.S65979.","journal-title":"J Inflamm Res."},{"issue":"2","key":"30_CR33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.12970\/2310-9971.2013.01.02.4","volume":"1","author":"R Negrulj","year":"2013","unstructured":"Negrulj R, Mooranian A, Al-Salami H. Potentials and limitations of bile acids in type 2 diabetes mellitus: applications of microencapsulation as a novel oral delivery system. J Endocrinol Diabetes Mellit. 2013;1(2):49\u201359. https:\/\/doi.org\/10.12970\/2310-9971.2013.01.02.4.","journal-title":"J Endocrinol Diabetes Mellit"},{"issue":"2","key":"30_CR34","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3109\/21691401.2014.971806","volume":"44","author":"A Mooranian","year":"2016","unstructured":"Mooranian A, Negrulj R, Chen-Tan N, Fakhoury M, Arfuso F, Jones F, et al. Advanced bile acid-based multi-compartmental microencapsulated pancreatic beta-cells integrating a polyelectrolyte-bile acid formulation, for diabetes treatment. Artif Cells Nanomed Biotechnol. 2016;44(2):588\u201395. https:\/\/doi.org\/10.3109\/21691401.2014.971806.","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"1","key":"30_CR35","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3109\/21691401.2014.934457","volume":"44","author":"A Mooranian","year":"2016","unstructured":"Mooranian A, Negrulj R, Arfuso F, Al-Salami H. Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic beta-cells. Artif Cells Nanomed Biotechnol. 2016;44(1):194\u2013200. https:\/\/doi.org\/10.3109\/21691401.2014.934457.","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"7","key":"30_CR36","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.3109\/21691401.2015.1069299","volume":"44","author":"A Mooranian","year":"2016","unstructured":"Mooranian A, Negrulj R, Arfuso F, Al-Salami H. Multicompartmental, multilayered probucol microcapsules for diabetes mellitus: formulation characterization and effects on production of insulin and inflammation in a pancreatic beta-cell line. Artif Cells Nanomed Biotechnol. 2016;44(7):1642\u201353. https:\/\/doi.org\/10.3109\/21691401.2015.1069299.","journal-title":"Artif Cells Nanomed Biotechnol."},{"issue":"2","key":"30_CR37","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/btpr.2223","volume":"32","author":"A Mooranian","year":"2016","unstructured":"Mooranian A, Negrulj R, Al-Salami H, Morahan G, Jamieson E. Designing anti-diabetic beta-cells microcapsules using polystyrenic sulfonate, polyallylamine, and a tertiary bile acid: morphology, bioenergetics, and cytokine analysis. Biotechnol Prog. 2016;32(2):501\u20139. https:\/\/doi.org\/10.1002\/btpr.2223.","journal-title":"Biotechnol Prog"},{"issue":"2","key":"30_CR38","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s12247-016-9248-7","volume":"11","author":"A Mooranian","year":"2016","unstructured":"Mooranian A, Negrulj R, Al-Salami H. Alginate-deoxycholic Acid Interaction and its impact on pancreatic \u0392-cells and insulin secretion and potential treatment of type 1 diabetes. J Pharm Innov. 2016;11(2):156\u201361.","journal-title":"J Pharm Innov"},{"issue":"3","key":"30_CR39","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4155\/tde-2015-0001","volume":"7","author":"A Mooranian","year":"2016","unstructured":"Mooranian A, Negrulj R, Al-Salami H. Flow vibration-doubled concentric system coupled with low ratio amine to produce bile acid-macrocapsules of beta-cells. Ther Deliv. 2016;7(3):171\u20138.","journal-title":"Ther Deliv"},{"issue":"6","key":"30_CR40","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1080\/02652048.2016.1228703","volume":"33","author":"A Mooranian","year":"2016","unstructured":"Mooranian A, Negrulj R, Al-Salami H. The impact of allylamine-bile acid combinations on cell delivery microcapsules in diabetes. J Microencapsul. 2016;33(6):569\u201374.","journal-title":"J Microencapsul"},{"issue":"1","key":"30_CR41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4155\/tde-2015-0001","volume":"6","author":"A Mooranian","year":"2016","unstructured":"Mooranian A, Negrulj R, Al-Salami H. The incorporation of water-soluble gel matrix into bile acid-based microcapsules for the delivery of viable beta-cells of the pancreas, in diabetes treatment: biocompatibility and functionality studies. Drug Deliv Transl Res. 2016;6(1):17\u201323. https:\/\/doi.org\/10.4155\/tde-2015-0001.","journal-title":"Drug Deliv Transl Res."},{"issue":"2","key":"30_CR42","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12668-016-0198-9","volume":"6","author":"A Mooranian","year":"2016","unstructured":"Mooranian A, Negrulj R, Al-Salami H. Primary bile acid chenodeoxycholic acid-based microcapsules to examine \u03b2-cell survival and the inflammatory response. BioNanoScience. 2016;6(2):103\u20139.","journal-title":"BioNanoScience."},{"issue":"2","key":"30_CR43","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1504\/IJNBM.2016.079684","volume":"6","author":"A Mooranian","year":"2016","unstructured":"Mooranian A, Negrulj R, Al-Salami H. Viability and topographical analysis of microencapsulated \u03b2-cells exposed to a biotransformed tertiary bile acid: an ex vivo study. Int J Nano Biomater. 2016;6(2):74\u201382. https:\/\/doi.org\/10.1504\/IJNBM.2016.079684.","journal-title":"Int J Nano Biomater"},{"issue":"2","key":"30_CR44","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1358\/mf.2008.30.2.1159652","volume":"30","author":"H Al-Salami","year":"2008","unstructured":"Al-Salami H, Butt G, Tucker I, Mikov M. Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats. Methods Find Exp Clin Pharmacol. 2008;30(2):107\u201313. https:\/\/doi.org\/10.1358\/mf.2008.30.2.1159652.","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"2","key":"30_CR45","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s13318-011-0060-y","volume":"37","author":"H Al-Salami","year":"2012","unstructured":"Al-Salami H, Butt G, Tucker I, Golocorbin-Kon S, Mikov M. Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet. 2012;37(2):99\u2013108. https:\/\/doi.org\/10.1007\/s13318-011-0060-y.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"30_CR46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/BF03191383","volume":"34","author":"H Al-Salami","year":"2009","unstructured":"Al-Salami H, Butt G, Tucker I, Fawcett PJ, Golocorbin-Kon S, Mikov I, et al. Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet. 2009;34(1):43\u201350. https:\/\/doi.org\/10.1007\/BF03191383.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"30_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-017-0473-5","author":"A Mooranian","year":"2018","unstructured":"Mooranian A, Negrulj R, Takechi R, Mamo JC, Al-Sallami H, Al-Salami H. The biological effects of the hypolipidaemic drug probucol incorporated into bile acid-microcapsules and fed daily for 4-weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory effects. Drug Deliv and Transl Res. 2018. https:\/\/doi.org\/10.1007\/s13346-017-0473-5(In press).","journal-title":"Drug Deliv and Transl Res"},{"issue":"211","key":"30_CR48","doi-asserted-by":"publisher","first-page":"211ra156","DOI":"10.1126\/scitranslmed.3006534","volume":"5","author":"F Engin","year":"2013","unstructured":"Engin F, Yermalovich A, Nguyen T, Hummasti S, Fu W, Eizirik DL, et al. Restoration of the unfolded protein response in pancreatic beta cells protects mice against type 1 diabetes. Sci Transll Med. 2013;5(211):211ra156. https:\/\/doi.org\/10.1126\/scitranslmed.3006534.","journal-title":"Sci Transll Med"},{"issue":"2","key":"30_CR49","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11095-017-2138-y","volume":"6","author":"A Mooranian","year":"2016","unstructured":"Mooranian A, Negrulj R, Salami HA. Viability and topographical analysis of microencapsulated \u03b2-cells exposed to a biotransformed tertiary bile acid: an ex vivo study. Int J Nano Biomater. 2016;6(2):74\u201382. https:\/\/doi.org\/10.1007\/s11095-017-2138-y.","journal-title":"Int J Nano Biomater"},{"issue":"10","key":"30_CR50","doi-asserted-by":"publisher","first-page":"e1005157","DOI":"10.1371\/journal.ppat.1005157","volume":"11","author":"A Shen","year":"2015","unstructured":"Shen A. A gut odyssey: the impact of the microbiota on clostridium difficile spore formation and germination. PLoS Pathog. 2015;11(10):e1005157. https:\/\/doi.org\/10.1371\/journal.ppat.1005157.","journal-title":"PLoS Pathog"},{"issue":"5","key":"30_CR51","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1053\/jhep.2001.23790","volume":"33","author":"C Einarsson","year":"2001","unstructured":"Einarsson C, Hillebrant CG, Axelson M. Effects of treatment with deoxycholic acid and chenodeoxycholic acid on the hepatic synthesis of cholesterol and bile acids in healthy subjects. Hepatology. 2001;33(5):1189\u201393. https:\/\/doi.org\/10.1053\/jhep.2001.23790.","journal-title":"Hepatology"},{"issue":"8","key":"30_CR52","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1211\/jpp\/61.08.0009","volume":"61","author":"K Yasukawa","year":"2009","unstructured":"Yasukawa K, Iida T, Fujimoto Y. Relative inhibitory activity of bile acids against 12-O-tetradecanoylphorbol-13-acetate-induced inflammation, and chenodeoxycholic acid inhibition of tumour promotion in mouse skin two-stage carcinogenesis. J Pharm Pharmacol. 2009;61(8):1051\u20136. https:\/\/doi.org\/10.1211\/jpp\/61.08.0009.","journal-title":"J Pharm Pharmacol"},{"key":"30_CR53","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.1997.272.5.g1249","author":"A Uchida","year":"1997","unstructured":"Uchida A, Yamada T, Hayakawa T, Hoshino M. Taurochenodeoxycholic acid ameliorates and ursodeoxycholic acid exacerbates small intestinal inflammation. Am J Physiol. 1997. https:\/\/doi.org\/10.1152\/ajpgi.1997.272.5.g1249.","journal-title":"Am J Physiol"},{"issue":"1","key":"30_CR54","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.toxlet.2014.04.001","volume":"228","author":"BL Woolbright","year":"2014","unstructured":"Woolbright BL, Li F, Xie Y, Farhood A, Fickert P, Trauner M, et al. Lithocholic acid feeding results in direct hepato-toxicity independent of neutrophil function in mice. Toxicol Lett. 2014;228(1):56\u201366. https:\/\/doi.org\/10.1016\/j.toxlet.2014.04.001.","journal-title":"Toxicol Lett"},{"issue":"35","key":"30_CR55","doi-asserted-by":"publisher","first-page":"31441","DOI":"10.1074\/jbc.M200474200","volume":"277","author":"J Yu","year":"2002","unstructured":"Yu J, Lo JL, Huang L, Zhao A, Metzger E, Adams A, et al. Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J Biol Chem. 2002;277(35):31441\u20137. https:\/\/doi.org\/10.1074\/jbc.M200474200.","journal-title":"J Biol Chem"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-019-00030-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s43440-019-00030-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-019-00030-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T21:05:07Z","timestamp":1610485507000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s43440-019-00030-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,13]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["30"],"URL":"https:\/\/doi.org\/10.1007\/s43440-019-00030-z","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,13]]},"assertion":[{"value":"26 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Al-Salami H has been and is currently receiving of funding from Beijing Nat-Med Biotechnology Co. Ltd. The other authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}